Incyte vs Zoetis

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (78 vs 79)
Incyte logo

Incyte

LeaderHealthcare Tech

Enterprise

Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.

AI VisibilityBeta
Overall Score
B78
Category Rank
#36 of 596
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
77
Gemini
75

About

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.

Full profile
Zoetis logo

Zoetis

LeaderHealthcare Tech

Animal Health

Zoetis (ZTS) reported ~$9.1B revenue in FY2024. World's largest animal health company developing medicines, vaccines, and diagnostics for companion animals and livestock. HQ: Parsippany, NJ.

AI VisibilityBeta
Overall Score
B79
Category Rank
#31 of 596
AI Consensus
66%
Trend
stable
Per Platform
ChatGPT
81
Perplexity
73
Gemini
84

About

Zoetis Inc. is the world's largest animal health company, developing, manufacturing, and commercializing medicines, vaccines, diagnostics, and other technologies for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish). Spun off from Pfizer in 2013, Zoetis has maintained its position as the global leader in animal health with approximately 300 product lines serving veterinarians, livestock producers, and pet owners in over 100 countries.

Full profile

AI Visibility Head-to-Head

78
Overall Score
79
#36
Category Rank
#31
82
AI Consensus
66
stable
Trend
stable
78
ChatGPT
81
77
Perplexity
73
75
Gemini
84
81
Claude
73
82
Grok
84

Key Details

Category
Enterprise
Animal Health
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Zoetis
Animal Health

Integrations

Only Incyte
Incyte is classified as company. Zoetis is classified as company (part of Pfizer).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.